Nature Publishes Promising Results on Treatment of First Patient in Genetix Pharmaceuticals, Inc.’s Phase 1/2 Beta-Thalassemia Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio (formerly Genetix Pharmaceuticals Inc.) an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin™ gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.

Back to news